Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01765803 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
A Early Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01765803 is a Early Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 6 participants.
The verdict
NCT01765803, a Early Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow to the circulation in a group of healthy humans. The types of cells we hope to collect are called CD34+ progenitor, or stem cells. These cells can be used in the laboratory to better understand a number of diseases and suggest new strategies for therapy. Perhaps the most important potential application of human stem cells is the generation of cells and tissues that could be used for cell-based therapies, as a renewable source of replacement cells and tissues to treat diseases including Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.
Interventions
- DRUG Mellaril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01765803
The ClinicalTrials.gov registry entry for NCT01765803 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mellaril is the first listed.
NCT01765803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01765803 about?
NCT01765803 is a clinical study titled "Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells". This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow to the circulation in a group of healthy humans. The types of cells we hope to collect are called CD34+ progenitor, or stem c...
What is the current status of trial NCT01765803?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2013-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01765803?
The interventions under investigation include: Mellaril (DRUG).
Who is sponsoring clinical trial NCT01765803?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.